Literature DB >> 33489115

Remdesivir therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials.

Charan Thej Reddy Vegivinti1, John M Pederson2, Kavitha Saravu3, Nitin Gupta3, Averi Barrett2, Amber R Davis4, Kevin M Kallmes2, Kirk W Evanson4.   

Abstract

PURPOSE: To perform a systematic review and meta-analysis of randomized controlled trials that examined remdesivir treatment for COVID-19.
MATERIALS AND METHODS: A systematic literature search was performed using Pubmed, Embase, and ClinicalTrials.gov to identify studies published up to October 25, 2020 that examined COVID-19 treatment with remdesivir. A total of 3 randomized controlled trials that consisted of 1691 patients were included in the meta-analysis.
RESULTS: The odds for mechanical ventilation (MV) or extracorporeal membrane oxygenation (ECMO) following treatment was significantly lower in the remdesivir group compared to the control group (OR = 0.48 [95% CI: 0.34; 0.69], p < 0.001). The odds of early (at day 14/15; OR = 1.42 [95% CI: 1.16; 1.74], p < 0.001) and late (at day 28/29; OR = 1.44 [95% CI: 1.16; 1.79], p = 0.001) hospital discharge were significantly higher in the remdesivir group compared to the control group. There was no difference in the odds for mortality in patients treated with remdesivir (OR = 0.77 [95% CI: 0.56; 1.06], p = 0.108).
CONCLUSIONS: Remdesivir attenuates disease progression, leading to lower odds of MV/ECMO and greater odds of hospital discharge for COVID-19 patients. However, remdesivir does not affect odds of mortality.
© 2020 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.

Entities:  

Keywords:  Antiviral agents; Coronavirus; SARS virus; Therapeutic uses

Year:  2021        PMID: 33489115      PMCID: PMC7806502          DOI: 10.1016/j.amsu.2020.12.051

Source DB:  PubMed          Journal:  Ann Med Surg (Lond)        ISSN: 2049-0801


  13 in total

1.  Statistical aspects of the analysis of data from retrospective studies of disease.

Authors:  N MANTEL; W HAENSZEL
Journal:  J Natl Cancer Inst       Date:  1959-04       Impact factor: 13.506

2.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.

Authors:  Safiya Richardson; Jamie S Hirsch; Mangala Narasimhan; James M Crawford; Thomas McGinn; Karina W Davidson; Douglas P Barnaby; Lance B Becker; John D Chelico; Stuart L Cohen; Jennifer Cookingham; Kevin Coppa; Michael A Diefenbach; Andrew J Dominello; Joan Duer-Hefele; Louise Falzon; Jordan Gitlin; Negin Hajizadeh; Tiffany G Harvin; David A Hirschwerk; Eun Ji Kim; Zachary M Kozel; Lyndonna M Marrast; Jazmin N Mogavero; Gabrielle A Osorio; Michael Qiu; Theodoros P Zanos
Journal:  JAMA       Date:  2020-05-26       Impact factor: 56.272

3.  Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.

Authors:  Christoph D Spinner; Robert L Gottlieb; Gerard J Criner; José Ramón Arribas López; Anna Maria Cattelan; Alex Soriano Viladomiu; Onyema Ogbuagu; Prashant Malhotra; Kathleen M Mullane; Antonella Castagna; Louis Yi Ann Chai; Meta Roestenberg; Owen Tak Yin Tsang; Enos Bernasconi; Paul Le Turnier; Shan-Chwen Chang; Devi SenGupta; Robert H Hyland; Anu O Osinusi; Huyen Cao; Christiana Blair; Hongyuan Wang; Anuj Gaggar; Diana M Brainard; Mark J McPhail; Sanjay Bhagani; Mi Young Ahn; Arun J Sanyal; Gregory Huhn; Francisco M Marty
Journal:  JAMA       Date:  2020-09-15       Impact factor: 56.272

4.  Statistical properties of methods based on the Q-statistic for constructing a confidence interval for the between-study variance in meta-analysis.

Authors:  Robbie C M van Aert; Marcel A L M van Assen; Wolfgang Viechtbauer
Journal:  Res Synth Methods       Date:  2019-01-28       Impact factor: 5.273

5.  Compassionate Use of Remdesivir for Patients with Severe Covid-19.

Authors:  Jonathan Grein; Norio Ohmagari; Daniel Shin; George Diaz; Erika Asperges; Antonella Castagna; Torsten Feldt; Gary Green; Margaret L Green; François-Xavier Lescure; Emanuele Nicastri; Rentaro Oda; Kikuo Yo; Eugenia Quiros-Roldan; Alex Studemeister; John Redinski; Seema Ahmed; Jorge Bernett; Daniel Chelliah; Danny Chen; Shingo Chihara; Stuart H Cohen; Jennifer Cunningham; Antonella D'Arminio Monforte; Saad Ismail; Hideaki Kato; Giuseppe Lapadula; Erwan L'Her; Toshitaka Maeno; Sumit Majumder; Marco Massari; Marta Mora-Rillo; Yoshikazu Mutoh; Duc Nguyen; Ewa Verweij; Alexander Zoufaly; Anu O Osinusi; Adam DeZure; Yang Zhao; Lijie Zhong; Anand Chokkalingam; Emon Elboudwarej; Laura Telep; Leighann Timbs; Ilana Henne; Scott Sellers; Huyen Cao; Susanna K Tan; Lucinda Winterbourne; Polly Desai; Robertino Mera; Anuj Gaggar; Robert P Myers; Diana M Brainard; Richard Childs; Timothy Flanigan
Journal:  N Engl J Med       Date:  2020-04-10       Impact factor: 91.245

6.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.

Authors:  Yeming Wang; Dingyu Zhang; Guanhua Du; Ronghui Du; Jianping Zhao; Yang Jin; Shouzhi Fu; Ling Gao; Zhenshun Cheng; Qiaofa Lu; Yi Hu; Guangwei Luo; Ke Wang; Yang Lu; Huadong Li; Shuzhen Wang; Shunan Ruan; Chengqing Yang; Chunlin Mei; Yi Wang; Dan Ding; Feng Wu; Xin Tang; Xianzhi Ye; Yingchun Ye; Bing Liu; Jie Yang; Wen Yin; Aili Wang; Guohui Fan; Fei Zhou; Zhibo Liu; Xiaoying Gu; Jiuyang Xu; Lianhan Shang; Yi Zhang; Lianjun Cao; Tingting Guo; Yan Wan; Hong Qin; Yushen Jiang; Thomas Jaki; Frederick G Hayden; Peter W Horby; Bin Cao; Chen Wang
Journal:  Lancet       Date:  2020-04-29       Impact factor: 79.321

7.  Remdesivir for the Treatment of Covid-19 - Final Report.

Authors:  John H Beigel; Kay M Tomashek; Lori E Dodd; Aneesh K Mehta; Barry S Zingman; Andre C Kalil; Elizabeth Hohmann; Helen Y Chu; Annie Luetkemeyer; Susan Kline; Diego Lopez de Castilla; Robert W Finberg; Kerry Dierberg; Victor Tapson; Lanny Hsieh; Thomas F Patterson; Roger Paredes; Daniel A Sweeney; William R Short; Giota Touloumi; David Chien Lye; Norio Ohmagari; Myoung-Don Oh; Guillermo M Ruiz-Palacios; Thomas Benfield; Gerd Fätkenheuer; Mark G Kortepeter; Robert L Atmar; C Buddy Creech; Jens Lundgren; Abdel G Babiker; Sarah Pett; James D Neaton; Timothy H Burgess; Tyler Bonnett; Michelle Green; Mat Makowski; Anu Osinusi; Seema Nayak; H Clifford Lane
Journal:  N Engl J Med       Date:  2020-10-08       Impact factor: 91.245

8.  Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.

Authors:  Calvin J Gordon; Egor P Tchesnokov; Emma Woolner; Jason K Perry; Joy Y Feng; Danielle P Porter; Matthias Götte
Journal:  J Biol Chem       Date:  2020-04-13       Impact factor: 5.157

9.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.

Authors:  Jing Yang; Ya Zheng; Xi Gou; Ke Pu; Zhaofeng Chen; Qinghong Guo; Rui Ji; Haojia Wang; Yuping Wang; Yongning Zhou
Journal:  Int J Infect Dis       Date:  2020-03-12       Impact factor: 3.623

10.  Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.

Authors:  Wei-Jie Guan; Wen-Hua Liang; Yi Zhao; Heng-Rui Liang; Zi-Sheng Chen; Yi-Min Li; Xiao-Qing Liu; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Chun-Quan Ou; Li Li; Ping-Yan Chen; Ling Sang; Wei Wang; Jian-Fu Li; Cai-Chen Li; Li-Min Ou; Bo Cheng; Shan Xiong; Zheng-Yi Ni; Jie Xiang; Yu Hu; Lei Liu; Hong Shan; Chun-Liang Lei; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Lin-Ling Cheng; Feng Ye; Shi-Yue Li; Jin-Ping Zheng; Nuo-Fu Zhang; Nan-Shan Zhong; Jian-Xing He
Journal:  Eur Respir J       Date:  2020-05-14       Impact factor: 16.671

View more
  8 in total

Review 1.  Scoping insight on antiviral drugs against COVID-19.

Authors:  Ahmed S Ali; Ibrahim M Ibrahim; Abdulhadi S Burzangi; Ragia H Ghoneim; Hanin S Aljohani; Hamoud A Alsamhan; Jehan Barakat
Journal:  Arab J Chem       Date:  2021-08-16       Impact factor: 5.165

2.  Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials.

Authors:  Charan Thej Reddy Vegivinti; Kirk W Evanson; Hannah Lyons; Izzet Akosman; Averi Barrett; Nicole Hardy; Bernadette Kane; Praneeth Reddy Keesari; Yashwitha Sai Pulakurthi; Erin Sheffels; Prasanth Balasubramanian; Richa Chibbar; Spandana Chittajallu; Kathryn Cowie; J Karon; Lauren Siegel; Ranita Tarchand; Caleb Zinn; Nitin Gupta; Kevin M Kallmes; Kavitha Saravu; Jillienne Touchette
Journal:  BMC Infect Dis       Date:  2022-01-31       Impact factor: 3.090

3.  Clinical outcomes of hospitalized COVID-19 patients treated with remdesivir: a retrospective analysis of a large tertiary care center in Germany.

Authors:  Kathrin Marx; Ksenija Gončarova; Dieter Fedders; Sven Kalbitz; Nils Kellner; Maike Fedders; Christoph Lübbert
Journal:  Infection       Date:  2022-05-12       Impact factor: 7.455

4.  Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials.

Authors:  Chih-Cheng Lai; Chao-Hsien Chen; Cheng-Yi Wang; Kuang-Hung Chen; Ya-Hui Wang; Po-Ren Hsueh
Journal:  J Antimicrob Chemother       Date:  2021-03-24       Impact factor: 5.790

Review 5.  A sustainable approach for the removal methods and analytical determination methods of antiviral drugs from water/wastewater: A review.

Authors:  Bahriye Eryildiz; Bahar Yavuzturk Gul; Ismail Koyuncu
Journal:  J Water Process Eng       Date:  2022-08-08

6.  Impact of perceptions and attitudes on air travel choices in the post-COVID-19 era: A cross-national analysis of stated preference data.

Authors:  Francesco Manca; Jacek Pawlak; Aruna Sivakumar
Journal:  Travel Behav Soc       Date:  2022-10-11

7.  Potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of COVID-19 patients: An overview.

Authors:  Mahsa Mohseni; Hosein Ameri; Morteza Arab-Zozani
Journal:  Front Med (Lausanne)       Date:  2022-09-15

8.  Remdesivir for the treatment of COVID-19.

Authors:  Kelly Ansems; Felicitas Grundeis; Karolina Dahms; Agata Mikolajewska; Volker Thieme; Vanessa Piechotta; Maria-Inti Metzendorf; Miriam Stegemann; Carina Benstoem; Falk Fichtner
Journal:  Cochrane Database Syst Rev       Date:  2021-08-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.